LANTHEUS HOLDINGS INC (LNTH) Stock News
NASDAQ:LNTH - Nasdaq - US5165441032 - Common Stock
LNTH Latest News and Analysis
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market
Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for...
NASDAQ:LNTH is showing decent growth, but is still valued reasonably.
Investors should take note ofLANTHEUS HOLDINGS INC (NASDAQ:LNTH), a growth stock that remains attractively priced.
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level.
Exploring the Growth Potential of NASDAQ:LNTH as It Nears a Breakout.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) qualifies as a high growth stock and is consolidating.
LNTH Makes Notable Cross Below Critical Moving Average
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
Short-term market predictions are fun, but rarely worth investing in. Here are two stocks we think will be winners no matter what happens with the market in 2025.
LNTH Crosses Below Key Moving Average Level
Why Lantheus Holdings Stock Won Big on Wednesday
Lantheus Announces Share Repurchase Program
Lantheus Announces Share Repurchase Program
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading...
Lantheus to Present at the Jefferies London Healthcare Conference
Lantheus to Present at the Jefferies London Healthcare Conference
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company...
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading...
Lantheus Reports Third Quarter 2024 Financial Results
Lantheus Reports Third Quarter 2024 Financial Results
Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the...
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company...